RETRO-C Cancer Biomarker Assays

Rapid Single-Plex Detection

Oncology Screening and Monitoring

The RETRO-C product line delivers targeted cancer biomarker detection through single-analyte lateral flow assays optimized for specific tumor markers. Our current portfolio includes assays for CEA (Carcinoembryonic Antigen), AFP (Alpha-Fetoprotein), PSA (Prostate-Specific Antigen), CA-125, CA-15-3, CA-19-9, and HE-4—biomarkers with established clinical utility in cancer screening, diagnosis, treatment monitoring, and recurrence detection.

Each RETRO-C assay is designed as a standalone test, allowing healthcare providers to select biomarkers most relevant to individual patient needs and clinical contexts. The single-plex format ensures maximum sensitivity and specificity for each analyte, avoiding the compromises sometimes necessary in multiplex panels. Sample types supported include whole blood, serum, and plasma, accommodating standard clinical specimen collection protocols.

Available Biomarkers:

CEA (Carcinoembryonic Antigen)
AFP (Alpha-Fetoprotein)
PSA (Prostate-Specific Antigen)
CA-125, CA-15-3, CA-19-9
HE-4

Ideal For

Oncology clinics, primary care screening programs, rural healthcare facilities, mobile health units, patient monitoring during chemotherapy, and early detection initiatives in resource-limited settings. The assays support screening programs targeting high-risk populations and provide accessible options for longitudinal monitoring.

Key Benefits:

Enables decentralized cancer screening
Reduces time to initial biomarker assessment
Supports risk stratification
Facilitates earlier referral to specialists
Improves access to diagnostic services in areas with limited laboratory infrastructure
Rapid format can improve patient engagement and reduce loss to follow-up in screening programs

Request Information View All Services